Navigation Links
Tokai Pharmaceuticals' galeterone well-tolerated in patients with advanced prostate cancer
Date:3/31/2012

CAMBRIDGE, Mass. and CHICAGO, Ill. -- Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study. The data will be presented in an oral presentation titled, "ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy nave patients with castration-resistant prostate cancer (CRPC)," abstract number CT-07, on Tuesday, April 3, 2012 at 3:05 p.m. (CDT) at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago.

CRPC is an advanced, difficult-to-treat form of prostate cancer that occurs when the disease progresses despite the use of anti-hormonal therapies. Galeterone is a small molecule, oral drug for the treatment of CRPC that disrupts the growth and survival of prostate cancer cells via a novel and proprietary triple mechanism of action.

"Because currently available therapeutic options to treat castration-resistant prostate cancer are limited, often poorly-tolerated and may fail because of resistance, patients are in urgent need of new safe and effective treatments," said Mary-Ellen Taplin, M.D., associate professor of medicine, director of genitourinary clinical research, Dana-Farber Cancer Institute, Harvard Medical School and co-lead researcher in the study. "These Phase 1 galeterone data, demonstrating minimal toxicities, improved PSA response and a reduction in tumor size, are exciting for those of us in the medical community treating this life-threatening cancer. I look forward to following the further development of galeterone as a promising approach in the treatment of prostate cancer."

The ARMOR1 study was led by co-principal investigators Dr. Taplin and Bruce Montgomery, M.D., associate professor of medical oncology at the University of Washington School of Medicine, and their colleagues at leading prostate cancer research centers in the United States. The Phase 1 proof-of-concept clinical trial, part of the ARMOR (Androgen Receptor Modulation Optimized for Response) clinical development program for the evaluation of galeterone, enrolled 49 patients and was a dose-finding study to evaluate escalating dose levels of galeterone. The study also evaluated safety and reduction in prostate-specific antigen (PSA) levels from baseline levels measured at first visit. Patients who responded to therapy had the option to continue treatment with galeterone in an extension arm of the trial.

Most side effects were minor and included fatigue, nausea and diarrhea. Early efficacy tests demonstrated that 49 percent of patients had prostate-specific antigen (PSA) reductions of 30 percent or more; 11 of these patients had reductions of 50 percent or more. In addition, CT scans revealed a significant reduction in tumor size for some patients.

"We are pleased with the results of our Phase 1 proof-of-concept study, which demonstrated galeterone tolerability and efficacy in a difficult-to-treat, resistant prostate cancer patient population," said Martin D. Williams, president and chief executive officer, Tokai Pharmaceuticals. "Galeterone is the only prostate cancer therapy in development that combines three distinct mechanisms of action in one compound for a unique multi-target approach. The reductions in PSA levels seen in nearly half of all patients evaluated in our Phase 1 study are meaningful in a dose-escalation study and supportive of our Phase 2 clinical trial set to initiate later this year."

In the Phase 1 study, researchers observed transient, non-serious elevated liver function tests in 15 patients, most of whom were asymptomatic. Eleven of these patients stopped galeterone treatment, and of those, six of seven patients were rechallenged and successfully returned to treatment with no significant recurrence in liver function test elevations.

A Phase 2 study evaluating long-term safety and efficacy of galeterone in CRPC patients is planned for the second half of 2012.


'/>"/>
Contact: Caton Lovett
caton@purecommunicationsinc.com
910-232-7166
Pure Communications Inc.
Source:Eurekalert

Related biology news :

1. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
2. 2012 Biotechnology and Pharmaceuticals: Forthcoming Conferences and Exhibitions
3. Study finds an increase of children accidentally poisoned with pharmaceuticals
4. Study Shows Sutro Biopharmas Biochemical Protein Synthesis Technology Enables Rapid Production and Scale-Up of Biopharmaceuticals
5. PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. Enter into a Licensing and Collaboration Agreement on PEP02 (MM-398), Nanoliposomal Irinotecan
6. Environmental risk assessment of pharmaceuticals inadequate
7. Brown licenses potential muscular dystrophy treatment to Tivorsan Pharmaceuticals
8. CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
9. Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule
10. NIH awards $8.5 million for research on pharmaceuticals for children
11. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/22/2017)... , Feb. 22, 2017 With the ... ABI Research identifies four technologies that innovative and ... secure significant share in the changing competitive landscape: ... passive authentication.   "Companies can no ... to security," says Dimitrios Pavlakis , Industry ...
(Date:2/16/2017)... SAN FRANCISCO , Feb. 16, 2017 /PRNewswire/ ... research, today announced that it has received Laboratory ... The CAP Accreditation is presented to laboratories that ... and who demonstrate scientifically rigorous processes. ... of excellence in laboratory practices. We,re honored to ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... Israel , March 27, 2017 DarioHealth ... with mobile health and big data solutions, today announced ... party insurance coverage option for U.S. consumers who want ... DarioHealth has signed strategic alliance agreements with ... verify insurance coverage benefits, and if approved, will supply ...
(Date:3/24/2017)... -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative ... and patent-protected processes to develop and market advanced products ...  that it will present at the Needham Healthcare Conference ... H. "Pete" Petit, Chairman and CEO, Michael J. ... , EVP and Chief Commercialization Officer, and Mark ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Strategic Business Report" report to their offering. ... This report analyzes the Global ... Annual estimates and forecasts are provided for the period 2014 through ... research. The report profiles 25 companies including many ...
(Date:3/24/2017)... NEW YORK , March 24, 2017 ... Composite ended the trading session at 5,817.69, down 0.07%; ... finish at 20,656.58; and the S&P 500 closed at ... session as 4 sectors closed in green, 4 sectors ... the day. This Friday, Stock-Callers.com has initiated reports coverage ...
Breaking Biology Technology: